TAK-279 (NDI-034858)
Moderate-to-Severe Plaque Psoriasis
Key Facts
About Takeda
Takeda is a global biopharmaceutical leader committed to delivering life-transforming treatments, with a strategic focus on rare diseases, oncology, neuroscience, and gastroenterology. Its position was solidified by the landmark $62 billion acquisition of Shire in 2019, which expanded its footprint in rare diseases and plasma-derived therapies. The company employs a modality-agnostic, externalized R&D strategy, leveraging deep internal expertise in biologics and small molecules while aggressively partnering to access cutting-edge science. Takeda's financial foundation is built on a portfolio of marketed products, with a disciplined capital allocation strategy aimed at fueling innovation and sustainable growth.
View full company profileOther Moderate-to-Severe Plaque Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| ICOTYDE (icotrokinra) | Johnson and Johnson Innovative Medicine | Approved |
| ILUMYA® (tildrakizumab-asmn) | Sun Pharmaceutical | Commercial |
| Iruxolimab (AK101) | Akeso | Approved |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Approved |
| Envudeucitinib (ESK-001) | Alumis | Phase 3 |
| ORKA-001 | Oruka Therapeutics | Phase 1/2 |